Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013

Zoufaly, Alexander; Kraft, Colleen S.; Schmidbauer, Caroline; Puchhammer-Stoeckl, Elisabeth

doi:10.1007/s15010-016-0936-5

Cited by 22 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of INSTI resistance reported in our study is similar to a recent study observing the prevalence of transmitted INSTI resistance in a Swiss HIV cohort [33] but is lower than those reported in other North American and European cohorts [15, 16, 27, 28]. This difference may in part be due to our method of defining drug resistance, which was restricted to individuals who had intermediate- to high-level INSTI resistance as defined by the Stanford University HIV Drug Resistance Database Genotypic Resistance Interpretation Algorithm version 7.0.1.…”

Section: Discussionsupporting

confidence: 89%

“…This difference may in part be due to our method of defining drug resistance, which was restricted to individuals who had intermediate- to high-level INSTI resistance as defined by the Stanford University HIV Drug Resistance Database Genotypic Resistance Interpretation Algorithm version 7.0.1. Other studies have defined INSTI resistance as individual [15, 16, 27, 33] and/or cumulative [16, 27] presence of mutations. Nevertheless, there is an increase in the prevalence of intermediate- to high-level INSTI resistance within our population from 2009 to 2016 (1 to 7 per 1000 ART-treated individuals), likely due to the increase in the number of individuals receiving INSTI-containing therapies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis

Kamelian

Lepik

Chau

et al. 2019

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Integrase strand transfer inhibitors (INSTIs) are highly efficacious and well tolerated antiretrovirals with fewer adverse side-effects relative to other classes of antiretrovirals. The use of INSTIs raltegravir, elvitegravir, and dolutegravir has increased dramatically over recent years. However, there is limited information about the evolution and prevalence of INSTI resistance mutations in clinical human immunodeficiency virus populations. Methods Human immunodeficiency virus-1-positive individuals ≥19 years were included if they received ≥1 dispensed prescription of antiretroviral therapy (ART) in British Columbia between 2009 and 2016 (N = 9358). Physician-ordered drug resistance tests were analyzed and protease inhibitor (PI), reverse-transcriptase inhibitor (RT), and INSTI resistance were defined as having ≥1 sample with a combined, cumulative score ≥30 by Stanford HIV Drug Resistance Algorithm version 7.0.1. Results Although most ART-treated individuals were tested for PI and RT resistance, INSTI resistance testing lagged behind the uptake of INSTIs among INSTI-treated individuals (11% in 2009; 34% in 2016). The prevalence of INSTI resistance was relatively low, but it increased from 1 to 7 per 1000 ART-treated individuals between 2009 and 2016 (P < .0001, R2 = 0.98). Integrase strand transfer inhibitor resistance mutations increased at integrase codons 66, 97, 140, 148, 155, and 263. Conclusions The prevalence of INSTI resistance remains low compared with PI and RT resistance in ART-treated populations but is expanding with increased INSTI use.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis

Kamelian

Lepik

Chau

et al. 2019

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Baseline TDR rates for integrase strand transfer inhibitors (INSTIs) are largely unknown, as resistance for this class is not routinely determined at baseline unless there is concern about transmitted INSTI resistance and the provider is considering an INSTI as part of the ART . Current evidence reveals no increase in mutations conferring resistance to INSTIs in countries such as Switzerland and Austria . However, recent data revealed a statistically significant increase in prevalence of resistance to INSTIs in British Columbia from 2009 to 2015 .…”

Section: Introductionmentioning

confidence: 91%

Prevalence of HIV‐1 transmitted drug resistance in the incarcerated population

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The surveillance of TDR to integrase strand-transfer inhibitors (INSTIs), a relatively new drug class approved for the treatment of HIV, has become increasingly important in recent years [ 5 , 6 ]. The integrase inhibitors raltegravir, dolutegravir and elvitegravir are increasingly used as first-line ART in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) [ 5 , 6 ]. Raltegravir was approved for clinical use in ART-experienced patients in 2009, and in 2012 it was approved for use in ARV-naive patients when used in combination with two NRTIs.…”

Section: Introductionmentioning

confidence: 99%

HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan

Tsai

Chen

et al. 2018

Oncotarget

View full text Add to dashboard Cite

The use of antiretroviral therapy has reduced rates of mortality and morbidity in patients with human immunodeficiency virus/acquired immune deficiency syndrome(HIV/AIDS). However, transmission of drug-resistant strains poses a challenge to control the spread of HIV-1. Primary resistance to integrase strand-transfer inhibitors (INSTIs) is rare despite their increased use. The prevalence of transmitted drug resistance (TDR) to INSTIs was 0.9% in northern Taiwan. This study was to analyse the prevalence and risk factors of TDR to INSTIs in southern Taiwan. In this study, we enrolled antiretroviral treatment-naïve HIV-1-infected subjects who underwent voluntary counselling and testing from 2013 to 2016 in southern Taiwan. Genotypic drug resistance, coreceptor tropism (CRT) and INSTI resistance were determined. Logistic regression was used to analyse the risk factors for INSTI polymorphic substitution. Sequences were obtained from 184 consecutive individuals, of whom 96.7% were men who have sex with men and 3.3% were heterosexual. Of the patients, 10% (19/183) had hepatitis B and 33.3% (61/183) had syphilis infection. Subtype B HIV-1 strains were found in 96.1% of the patients. Fifteen patients (8.4%, 15/178) harboured nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors or protease inhibitors resistance. CCR-5 coreceptors were used by 71.4% (130/184) of the patients. None of the patients had INSTI resistance-associated mutations, however 16 patients had INSTI polymorphic substitutions, and they were associated with a higher HIV viral load (p = 0.03, OR 2.4, CI 1.1–5.3) and syphilis infection (p = 0.03, OR 3.7, CI 1.1–12.0). In conclusion, no signature INSTI resistance-associated mutations were detected in our cohort. Continued monitoring of TDR to INSTI is needed due to the increased use of INSTIs.

show abstract

Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013

Cited by 22 publications

References 23 publications

Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis

Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis

Prevalence of HIV‐1 transmitted drug resistance in the incarcerated population

HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan

Contact Info

Product

Resources

About